Otros idiomas Candel Therapeutics, Inc.

Acciones

CADL

US1374041093

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 31/05/2024			Varia. Cinco días.	Varia. 1 de enero.
8,9 ^USD	+3,25 %		+14,10 %	+505,44 %

30/05	La FDA concede la designación de medicamento huérfano a CAN-3110 de Candel Therapeutics para tratar el glioma de alto grado recurrente	MT
23/05	Candel Therapeutics informa de la supervivencia global prolongada en el ensayo clínico de fase 2 de Can-2409 para el cáncer de pulmón no microcítico avanzado en pacientes que no responden al tratamiento con inhibidores de los puntos de control inmunitarios en la reunión anual de Asco de 2024	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma	30/05
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting	23/05
Candel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Sector Update: Health Care Stocks Decline Thursday Afternoon	11/04
Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug	11/04
Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors	09/04
March Jobs Growth Exceed Expectations, Lifting US Equity Futures Pre-Bell	05/04
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	05/04
Jobs Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday	05/04
Top Premarket Gainers	05/04
Candel Therapeutics Shares Surge Premarket Following 'Positive' Phase 2 Results From Non-Metastatic Pancreatic Cancer Trial	05/04
Top Midday Gainers	04/04
Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer	04/04
Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma	28/03
Candel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Candel Therapeutics, Inc. Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate	05/03
Sector Update: Health Care Stocks Decline Late Afternoon	13/02
Sector Update: Health Care	13/02
Candel Therapeutics Gets FDA Fast Track Label For Treatment of Recurrent High-Grade Glioma	13/02
Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma	13/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Candel Therapeutics, Inc.

Acciones

CADL

US1374041093

Otros idiomas

Filtros